Cost–Utility Analysis of Short- Versus Long-Course Palliative Radiotherapy in Patients With Non–Small-Cell Lung Cancer

Abstract

In these poor-prognosis non-small-cell lung cancer patients, the estimated cost-utility ratio for the palliative 10 x 3-Gy schedule was acceptable according to current economic standards. However, the additional costs for the protracted schedule were justified not by improved quality of life but by longer survival.